Welcome to our dedicated page for Imac Hldgs news (Ticker: BACK), a resource for investors and traders seeking the latest updates and insights on Imac Hldgs stock.
IMAC Holdings Inc (BACK) delivers innovative non-invasive medical treatments through its network of IMAC Regeneration Centers and BackSpace clinics. This news hub provides investors and healthcare professionals with timely updates on the company’s advancements in integrative medicine and value-based care.
Access official press releases, earnings reports, and regulatory filings alongside analysis of clinical developments in regenerative therapies. Track key initiatives including treatment protocol innovations, partnership announcements, and research breakthroughs in proteomic diagnostics.
Our curated news collection enables you to monitor:
• Quarterly financial performance and growth metrics
• Regulatory milestones for new treatment approvals
• Clinical study results validating non-invasive approaches
• Strategic expansions of rehabilitation center networks
Bookmark this page for consolidated access to verified information about IMAC’s position in the evolving healthcare landscape. Check regularly for updates on conservative care alternatives reshaping orthopedic treatment paradigms.
Ignite Proteomics, a subsidiary of IMAC Holdings (Nasdaq: BACK), has announced groundbreaking data showing MHC-II protein expression as a superior predictor of pembrolizumab (Keytruda®) response compared to PD-L1. The findings will be presented at the upcoming National Comprehensive Cancer Network (NCCN) Annual Conference.
The study, conducted using I-SPY 2 clinical trial results, evaluated five different PD-L1 antibodies, including the commonly used companion diagnostic. Only MHC-II expression demonstrated statistically significant correlation with patient outcomes. Patients with higher MHC-II protein levels showed nearly double the response rate compared to unselected patients.
The I-SPY 2 trial, focusing on high-risk stage II and III breast cancer patients undergoing neoadjuvant treatment, is a multicenter, adaptive platform trial. The research suggests that MHC-II testing could significantly improve care by enabling more precise therapy decisions, particularly in cancer types where no biomarker testing is currently used.
Ignite Proteomics, a subsidiary of IMAC Holdings (Nasdaq: BACK), has completed the transfer of PLA code 0249U for its proteomic breast cancer assay, previously owned by Theralink Technologies. The code, listed on the Medicare Clinical Laboratory Fee Schedule with a reimbursement rate of $2,219.13, is covered under Palmetto GBA MolDx's 'Proteomics Testing' article (A59636).
The company's proteomic assay measures functional protein activity in breast tumors, offering oncologists data on potential patient responses to targeted therapies. The test is conducted in Ignite's CLIA-certified, CAP-accredited, and NY State-approved laboratory. This acquisition integrates both laboratory capabilities and intellectual property rights, positioning Ignite Proteomics to advance in precision oncology.
Ignite Proteomics, a subsidiary of IMAC Holdings (Nasdaq: BACK), has published a significant study in the British Journal of Cancer demonstrating the superiority of protein activation analysis in predicting breast cancer therapy response. The research reveals that direct assessment of protein activation provides better prediction of therapeutic outcomes compared to genomic profiling alone.
The study found that patients with functional activation of the AKT-mTOR signaling axis showed worse response to standard first-line treatment with CDK4/6 inhibitors. Importantly, genomic mutations in PIK3CA, PTEN, or AKT genes showed no correlation with protein activation status or patient outcomes.
The company's Reverse Phase Protein Array (RPPA)-based proteomic assay measures protein activation within the AKT-mTOR pathway, offering the only commercially available and clinically validated test that measures both expression and activation levels of drug targets in breast tumors. This approach enables more precise identification of patients likely to benefit from specific targeted therapies.
IMAC Holdings (NASDAQ: BACK) has launched Ignite Proteomics , a subsidiary focused on protein-based cancer treatment selection. The new venture aims to disrupt the multi-billion-dollar genomic testing market, with an immediate addressable market of $600M in its current clinically approved indication.
Unlike traditional genomic testing, Ignite's multi-protein test provides real-time insights into tumor behavior and drug response, particularly for antibody-drug conjugates (ADCs) and immunotherapies. The platform features novel biomarkers protected by licensed patents, offering physicians enhanced capabilities to select effective treatments and avoid trial-and-error approaches.
The company is actively collaborating with leading cancer centers to expand clinical evidence and integrate its test into routine care. The platform is particularly focused on breast cancer treatment guidelines and aims to provide more accurate insights than traditional gene-based testing methods.
IMAC Holdings (NASDAQ: BACK) has received a deficiency notification from Nasdaq due to its failure to timely file its Q3 2024 Form 10-Q. The company now has until January 21, 2024, to submit a compliance plan. If Nasdaq accepts the plan, IMAC may receive up to 180 calendar days (until May 19, 2025) to regain compliance. While the notice has no immediate effect on IMAC's stock listing, failure to regain compliance could result in delisting from Nasdaq Capital Market. The company intends to submit a compliance plan within the 60-day period but cannot guarantee success in maintaining its listing.
IMAC Holdings (NASDAQ: BACK) has received an extension from Nasdaq until February 17, 2025 to regain compliance with Listing Rule 5250(c)(1) by filing its Q2 2024 Form 10-Q. The delay in filing is attributed to three main factors: the acquisition of assets from Theralink Technologies, the exchange of Convertible Preferred Stocks and warrants, and staffing challenges including the temporary loss of a key financial staff member. The extension does not immediately affect the company's listing or trading status on the Nasdaq Capital Market.
IMAC Holdings Inc. (Nasdaq: BACK) has launched a new subsidiary, Ignite Proteomics , introducing a groundbreaking precision oncology assay for breast cancer treatment using Reverse Phase Protein Array (RPPA) technology. This follows IMAC's acquisition of key assets from Theralink Technologies, Inc. A landmark clinical case study published in npj Precision Oncology demonstrates the power of RPPA in precision oncology.
The case study highlights a 57-year-old woman with metastatic triple-negative breast cancer who achieved a complete response to therapy guided by Ignite's RPPA-based analysis. The assay identified HER2 expression and activation, missed by conventional methods, leading to successful treatment with trastuzumab deruxtecan (T-DXd).
Ignite Proteomics offers the only commercially available and clinically validated assay measuring both expression and activated protein drug target levels in breast tumors, potentially revolutionizing targeted cancer therapies.
IMAC Holdings (NASDAQ: BACK) has received a deficiency notification from Nasdaq due to the delayed filing of its Q2 2024 Form 10-Q. This non-compliance with Nasdaq Listing Rule 5250(c)(1) does not immediately affect the company's listing on the Nasdaq Capital Market. IMAC has until October 20, 2024, to submit a compliance plan and could potentially receive an extension until February 17, 2025, to regain compliance if Nasdaq accepts the plan. The company is working to file the Form 10-Q and take necessary steps to maintain its Nasdaq listing. However, there is no guarantee of success, and IMAC could face delisting if it fails to meet the requirements within the given timeframe.
IMAC Holdings has appointed Dr. Peter Beitsch and Dr. Matthew Schwartz to its Board of Directors, effective June 26, 2024. This strategic move aims to advance IMAC’s position in proteomics and precision medicine. Dr. Schwartz, with over 18 years of experience in radiotherapy and precision oncology, and Dr. Beitsch, with a background in surgical oncology and genomics, will contribute their expertise to guide IMAC's strategic initiatives. Their appointments align with the company's mission to revolutionize cancer treatment through proteomic technologies.
IMAC Holdings announced a major leadership transition, appointing Faith Zaslavsky as CEO, succeeding Jeff Ervin. This move aims to drive forward its newly acquired assets in the proteomics and precision medicine industry.
Zaslavsky brings 23 years of experience in the genomic space, having previously served as COO and CEO of Theralink Technologies and President of Oncology at Myriad Genetics. Her leadership is expected to enhance IMAC's mission of providing personalized treatment plans for cancer patients.
IMAC's RPPA technology, proven through clinical trials as a superior indicator for drug selection in breast cancer, is set to become an essential test for various cancers. The board now consists of three independent members following the resignation of co-founders Dr. Matt Wallis and Jeff Ervin, with Ervin continuing as a transition consultant.
